Episode 9: Neo-adjuvant Nivolumab - The Backstory
Upon completion of this activity, participants will be able to:
- Articulate the reasoning behind an FDA oncology drug approval.
- Identify the relevant sections of the drug USPI where information is located.
- Integrate this information into their clinical practice.
Review video content here.
Time to Complete Activity: 75 minutes
In This Episode:
- Jeevan Puthiamadathil, MD – Oncologist, Division of Oncology 2, FDA
- Oladimeji Akinboro, MD – Oncologist, Division of Oncology 2, FDA
- Abderrahim Oukessou, MD – Vice President, Development Program Lead, Oncology, Bristol-Myers Squibb
- Patrick Forde, MD – Johns Hopkins University, Clinical Investigator
- Dawn Vasco – Patient
- Kevin Chen, PharmD – University of North Carolina Medical Center, Pharmacist
Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated.